PE57198A1 - Formula de liberacion prolongada - Google Patents

Formula de liberacion prolongada

Info

Publication number
PE57198A1
PE57198A1 PE00015497A PE00015497A PE57198A1 PE 57198 A1 PE57198 A1 PE 57198A1 PE 00015497 A PE00015497 A PE 00015497A PE 00015497 A PE00015497 A PE 00015497A PE 57198 A1 PE57198 A1 PE 57198A1
Authority
PE
Peru
Prior art keywords
weight
composition
content
propil
spheroids
Prior art date
Application number
PE00015497A
Other languages
English (en)
Spanish (es)
Inventor
Marie Sherman Deborah
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21762972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE57198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of PE57198A1 publication Critical patent/PE57198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE00015497A 1996-03-25 1997-03-04 Formula de liberacion prolongada PE57198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1400696P 1996-03-25 1996-03-25

Publications (1)

Publication Number Publication Date
PE57198A1 true PE57198A1 (es) 1998-10-10

Family

ID=21762972

Family Applications (1)

Application Number Title Priority Date Filing Date
PE00015497A PE57198A1 (es) 1996-03-25 1997-03-04 Formula de liberacion prolongada

Country Status (33)

Country Link
EP (2) EP2881110A1 (enExample)
JP (2) JP4771565B2 (enExample)
KR (1) KR101096512B1 (enExample)
CN (2) CN1090018C (enExample)
AR (1) AR006519A1 (enExample)
AT (1) ATE257011T1 (enExample)
AU (1) AU727653B2 (enExample)
BR (1) BR9701304A (enExample)
CA (1) CA2199778C (enExample)
CO (1) CO4761054A1 (enExample)
CY (1) CY2442B1 (enExample)
CZ (1) CZ291637B6 (enExample)
DE (1) DE69727000T2 (enExample)
DK (1) DK0797991T3 (enExample)
EG (1) EG24198A (enExample)
ES (1) ES2210454T3 (enExample)
HU (1) HU224617B1 (enExample)
IL (1) IL120382A (enExample)
IN (1) IN187337B (enExample)
NO (2) NO320355B1 (enExample)
NZ (1) NZ314442A (enExample)
PA (1) PA8426401A1 (enExample)
PE (1) PE57198A1 (enExample)
PL (2) PL195564B1 (enExample)
PT (1) PT797991E (enExample)
RU (1) RU2176912C2 (enExample)
SK (1) SK281530B6 (enExample)
SV (1) SV1997000015A (enExample)
TR (1) TR199700190A2 (enExample)
TW (1) TW493993B (enExample)
UA (1) UA44904C2 (enExample)
UY (1) UY24613A1 (enExample)
ZA (1) ZA972403B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
JP3379461B2 (ja) * 1998-08-06 2003-02-24 三菱電機株式会社 コア部材の積層金型装置、コア部材の積層方法および電動機
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
SK286865B6 (sk) * 1999-05-20 2009-06-05 Elan Pharma International Limited Multičasticový farmaceutický prostriedok s riadeným uvoľňovaním selektívneho inhibítora spätného príjmu serotonínu a jeho použitie
ES2162746B1 (es) * 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
PL365895A1 (en) * 2000-10-19 2005-01-10 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
HUP0104872A3 (en) * 2001-11-13 2004-04-28 Egis Gyogyszergyar Nyilvanosan New polymorphic forms of venlafaxine, process for their preparation, pharmaceutical compositions containing them and their use
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2003082261A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Extended release venlafaxine formulations
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
WO2003082805A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts
US20060246132A1 (en) * 2003-02-07 2006-11-02 Fjalar Johannsson Sustained release formulations of venlafaxine
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
EP1473030B2 (en) * 2003-05-02 2014-05-14 Dexcel Ltd. Extended release Venlafaxine tablet formulation
IN2003MU00504A (enExample) * 2003-06-05 2005-05-13 Alembic Ltd
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
ATE336988T1 (de) 2003-07-30 2006-09-15 Pharmathen Sa Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
DE10359154A1 (de) 2003-12-16 2005-07-28 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I
PL1711169T3 (pl) 2004-02-04 2007-10-31 Alembic Ltd Powlekane tabletki chlorowodorku wenlafaksyny o wydłużonym czasie uwalniania
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100463676C (zh) * 2004-11-11 2009-02-25 成都康弘药业集团股份有限公司 一种盐酸文拉法辛控释片制剂及其制备方法
ITFI20050206A1 (it) * 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
PL2010158T3 (pl) 2006-04-26 2016-09-30 Formulacje o kontrolowanym uwalnianiu zawierające niepowlekaną odrębną jednostkę(-i) i macierz o przedłużonym uwalnianiu
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
KR100791194B1 (ko) * 2006-06-12 2008-01-02 코오롱제약주식회사 염산 벤라팍신의 경구 투여용 서방성 펠렛 및 그 제조방법
CA2789006C (en) * 2010-02-03 2018-11-27 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
EP2670409B1 (en) 2011-01-31 2018-04-18 Serotech, LLC Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
AU2018269557B2 (en) 2017-05-17 2021-06-03 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺
JP2023127913A (ja) * 2022-03-02 2023-09-14 共和薬品工業株式会社 ベンラファキシン塩酸塩含有顆粒
KR20250121244A (ko) 2024-02-03 2025-08-12 교와 야쿠힝 고교 가부시키가이샤 벤라팍신염산염 함유 서방성 과립의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
DK0639374T3 (da) * 1993-06-28 2002-05-06 American Home Prod Nye behandlingsmetoder ved anvendelse af phenethylderivater
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada

Also Published As

Publication number Publication date
TR199700190A2 (xx) 1997-10-21
CA2199778C (en) 2005-12-20
CZ77297A3 (en) 1997-11-12
NO320355B1 (no) 2005-11-28
HK1056686A1 (en) 2004-02-27
JPH107552A (ja) 1998-01-13
NZ314442A (en) 1999-06-29
PA8426401A1 (es) 2000-05-24
MX9701873A (es) 1997-09-30
CA2199778A1 (en) 1997-09-25
RU2176912C2 (ru) 2001-12-20
PL195564B1 (pl) 2007-10-31
BR9701304A (pt) 1998-09-29
TW493993B (en) 2002-07-11
HUP9700589A3 (en) 2001-03-28
SV1997000015A (es) 1997-08-13
DE69727000T2 (de) 2004-06-09
NO971206D0 (no) 1997-03-14
AU1640097A (en) 1997-10-02
CZ291637B6 (cs) 2003-04-16
NO20050379L (no) 1997-09-26
HUP9700589A2 (en) 1997-09-29
NO971206L (no) 1997-09-26
CO4761054A1 (es) 1999-04-27
IN187337B (enExample) 2002-03-30
ES2210454T3 (es) 2004-07-01
CY2442B1 (en) 2004-11-12
AR006519A1 (es) 1999-09-08
EP0797991A1 (en) 1997-10-01
UA44904C2 (uk) 2002-03-15
KR970064599A (ko) 1997-10-13
HU9700589D0 (en) 1997-05-28
EP0797991B1 (en) 2004-01-02
HU224617B1 (hu) 2005-11-28
PL318954A1 (en) 1997-09-29
EG24198A (en) 2008-10-14
IL120382A0 (en) 1997-07-13
IL120382A (en) 2003-06-24
ATE257011T1 (de) 2004-01-15
JP2008156374A (ja) 2008-07-10
DK0797991T3 (da) 2004-04-05
PL188444B1 (pl) 2005-02-28
ZA972403B (en) 1998-09-21
EP2881110A1 (en) 2015-06-10
SK281530B6 (sk) 2001-04-09
PT797991E (pt) 2004-05-31
SK30197A3 (en) 1997-10-08
CN1164389A (zh) 1997-11-12
AU727653B2 (en) 2000-12-21
UY24613A1 (es) 2000-09-29
KR101096512B1 (ko) 2014-11-28
JP4771565B2 (ja) 2011-09-14
DE69727000D1 (de) 2004-02-05
CN1403077A (zh) 2003-03-19
CN1090018C (zh) 2002-09-04

Similar Documents

Publication Publication Date Title
PE57198A1 (es) Formula de liberacion prolongada
ES2100046T3 (es) Composiciones antipireticas y analgesicas que contienen r-ketorolaco opticamente puro.
CO4750836A1 (es) Nuevos medicamentos y utilizacion (1-metiletil)-8-azoniabiciclo-[3.2.1]octnao y su uso en pre- paraciones medicas
RU2008143545A (ru) Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
YU47204B (sh) Derivati didehidro-vitamina d3
ES2119984T3 (es) Nuevos compuestos propinil bi-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
ES2110747T3 (es) Composicion cosmetica que contiene precursores de ceramida.
MY125414A (en) Aminopropylphosphinic acids
PE20000329A1 (es) Derivados de indol y composiciones farmaceuticas que los contienen
AR003435A1 (es) Una composicion farmaceutica oral organolepticamente aceptable de etodolac s (+)-
UY25234A1 (es) Formulación de liberación prolongada de venlafaxina
ES2176542T3 (es) Composicion de resina poliolefinica, y una pelicula laminada que la contiene.
PE29798A1 (es) Acetidinas
ES2117474T3 (es) Derivados n-sustituidos del 4-hidroxiindol y composiciones de tinte de fibras queratinicas que los contienen.
AR016824A1 (es) Composiciones solidas o semisolidas de uso oral, que contienen calcio y un acidulante; procedimiento para prerarar dichas composiciones; uso de compuestosde calcio como inhbidores de la erosion dental
ES2119326T3 (es) Compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2120145T3 (es) Compuestos bi-aromaticos acetilenados con grupo adamantilo, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2124069T3 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
AR000490A1 (es) Una composición que absorbe humedad y un cable óptico que la comprende
ES2192779T3 (es) Modificacion cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico.
AR023511A1 (es) Composicion que comprende (s) y (r) 5-amino-3-ciano-1-(2,6-dicloro-4-trifluorometilfenil)-4-trifluoro-metilsulfinilpirazol, dichos compuestos aislados y usos de los mismos como plaguicida

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term